Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias
- PMID: 2732780
- DOI: 10.1080/1120009x.1989.11738878
Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias
Abstract
Thirty cases of acute leukemia in patients over 15 years of age (18 males and 12 females) were treated with combinations containing mitoxantrone between January 1986 and August 1987 at the Kuwait Cancer Control Center. Acute nonlymphoblastic leukemia (ANLL) cases received mitoxantrone 10 mg/m2/day, days 1-3, cytosine arabinoside (Ara-C) 100 mg/m2 continuous daily infusion, days 1-5, and 6-thioguanine 100 mg/m2/day, days 1-5. Cases of acute lymphoblastic leukemia (ALL) received mitoxantrone 10 mg/m2/day, days 1-3, vincristine 1.4 mg/m2 days 1, 8, 15 and 22 and prednisone 40 mg/m2/day, days 1-22, then tapered down over one week. There were 16 cases of newly diagnosed ANLL, 9 cases of newly diagnosed ALL and 5 cases of relapsing leukemias. The 30 patients received 59 courses of therapy. The main toxicity was pancytopenia which occurred following all courses. It started following 75% of courses on day 8, lasted between 8-10 days and then rapidly recovered. In cases of ALL, the platelet count was much less affected in subsequent courses. Nausea and vomiting was a minor problem and occurred following 19% of courses, and in the majority was mild. Mucositis occurred following 30% of courses, and was mainly of moderate degree starting one week following the start of the course, and lasted about one week. Alopecia in the 25 newly diagnosed cases occurred in 18 cases (9 partial and 9 complete).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.Semin Oncol. 1984 Sep;11(3 Suppl 1):36-40. Semin Oncol. 1984. PMID: 6385264 Clinical Trial.
-
Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.Anticancer Drugs. 1995 Apr;6(2):224-8. doi: 10.1097/00001813-199504000-00005. Anticancer Drugs. 1995. PMID: 7795271
-
Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.Acta Haematol. 1992;87(1-2):54-7. doi: 10.1159/000204714. Acta Haematol. 1992. PMID: 1585771
-
A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.Hematol Oncol. 2004 Jun;22(2):43-53. doi: 10.1002/hon.726. Hematol Oncol. 2004. PMID: 15386563 Review.
-
Mitoxantrone.2020 Feb 19. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Feb 19. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643266 Free Books & Documents. Review.
Cited by
-
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.Drugs Aging. 1996 Aug;9(2):122-47. doi: 10.2165/00002512-199609020-00007. Drugs Aging. 1996. PMID: 8820798 Review.
-
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007. Drugs. 1991. PMID: 1711446 Review.
MeSH terms
Substances
LinkOut - more resources
Medical